Folks,
Here are a few reasons why VolitionRx (VNRX) is worth having on your radar...
1. Proven Licensing Model — The company has already demonstrated its business model works through the Antech partnership, which has generated $23 million in upfront and milestone payments to date, with ongoing revenue from kit and component sales.
2. Strong Intellectual Property — Volition holds 71 granted patents across 56 patent families, with protection extending to 2044, providing a substantial competitive moat if the technology proves clinically valuable.
3. Multiple Billion-Dollar Markets — The company is targeting several large addressable markets including veterinary cancer testing ($1B+), human cancer screening ($4B), and sepsis diagnostics ($3B in ICU/ED settings alone).
4. Asset-Light Business Model — By licensing technology rather than building labs and sales teams, Volition can scale without massive capital expenditure, potentially leading to higher margins if partnerships materialize.
5. Commercial Validation Already Exists — Unlike many development-stage companies, Volition has a product generating real revenue through its Nu.Q Vet Cancer Test, with over 120,000 tests and components sold in 2024.
6. Partnerships With Industry Leaders — The company has secured agreements with respected names including IDEXX, Antech, Fujifilm, Werfen, and Hologic Diagenode, lending credibility to its technology.
Anyways...
That's all for now!
Until Next Time,
-ZT Team
Tidak ada komentar:
Posting Komentar